AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04079569 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living
Description: In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout.
Study NCT01642654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The WG was submitted to a 16-week WEP, with combined aerobic and resistance exercises in three weekly sessions. Water temperature was approximately 30º C with an average ambient temperature of 34° C. The pool had water levels ranging between 1,20 and 1,40 meters deep.
Study NCT01642654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational lectures
Description: Educational lectures
Study NCT01269788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: 20 mg , oral , daily 30 mins before breakfast, for 6 weeks
Study NCT03336788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS - ) MagPro®
Description: 20 sessions navigated with Conventional Transcranial Magnetic Stimulation
Study NCT03336788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: virtual reality for displaying interactive virtual environments
Description: 20 sessions navigated with virtual reality
Study NCT04349696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitiglinide
Description: Day 1: one tablet of Mitiglinide 10mg with 240 ml of water approximately 5 mins before breakfast. An indwelling non-heparin catheter will be placed in an antecubital vein of the forearm or direct venipuncture will be adopted for blood sample collection at belowing time point:~For PK evaluation:~-30 (Predose), 5, 10, 15, 20, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10 hr post dose (a total of 17 samples per subject)~For PD evaluation:~-30 (Predose), 15, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0 hours post dose (a total of 8 samples per subject)
Study NCT04349696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitiglinide
Description: Day 1: one tablet of Mitiglinide 10mg with 240 ml of water approximately 5 mins before breakfast. An indwelling non-heparin catheter will be placed in an antecubital vein of the forearm or direct venipuncture will be adopted for blood sample collection at belowing time point:~For PK evaluation:~-30 (Predose), 5, 10, 15, 20, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10 hr post dose (a total of 17 samples per subject)~For PD evaluation:~-30 (Predose), 15, 30 min, 1.0, 1.5, 2.0, 3.0, 4.0 hours post dose (a total of 8 samples per subject)
Study NCT01632306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2090314
Description: LY2090314 administered IV
Study NCT01632306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: FOLFOX administered IV
Study NCT01632306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered IV
Study NCT04908527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking to OR
Description: Patients, after being prepared for the OR, walk to the operating room
Study NCT02605538 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination with vaccine against hepatitis A and B
Description: Vaccination against hepatitis A and B
Study NCT01063803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATN-103
Description: A single subcutaneous injection of ATN-103 every 4 weeks (approx 13 SC injections during the study)
Study NCT01269788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 20 mg , oral , daily 30 mins before breakfast, for 6 weeks
Study NCT01269788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral , daily 30 mins before breakfast, for 6 weeks
Study NCT03906188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LitEmotion
Description: LitEmotion is a serious video game programmed for helping managing emotions. The experimental group will play during 3 weeks while the control group will not play. The sample will play during 21 days, one session daily, around 45 minutes. After the 21 sessions the group will stop playing during 3 weeks. Therefore, the scales are done three times. In the very beginning (before playing), 21 days after playing, and, finally, 21 days no playing.
Study NCT01393015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated settings on the oxygen delivery device
Description: FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal. Patients keep using the same device for duration of hospitalization.
Study NCT01393015 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual settings with FreeO2 system in collection mode
Description: Oxygen flow delivery is adjust by nurse and respiratory therapists. Standard medical treatment. Patients keep using the same device for duration of hospitalization.
Study NCT00910468 — intervention group
Intervention type: PROCEDURE
Intervention: Robot-assisted Laparoscopic myomectomy
Description: Robot-assisted Laparoscopic myomectomy
Study NCT00877474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM01183
Description: Vials containing 0.2 mg of PM01183 as powder for concentrate for solution for infusion
Study NCT01125501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protandim
Description: The product Protandim used in this study have ingredients derived from five botanical sources \[Bacopa monniera, Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), and Curcuma longa (turmeric)\].
Study NCT01125501 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protandim
Description: The product Protandim used in this study have ingredients derived from five botanical sources \[Bacopa monniera, Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), and Curcuma longa (turmeric)\].
Study NCT02051816 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video Laryngoscopy
Study NCT04349761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01924143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-9855
Description: radiolabeled (100 µCi \[14C\]-Labeled) TD-9855 (20 mg)
Study NCT00803140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cautery vs Active Control Arm (Scalpel)
Description: Interventions: The cautery used will be the standard operating room monopolar cautery used at our institution. The cautery will be used on a cut setting of 20 with a blend setting of zero (pure cut). A standard protected needle tip cautery will be used.~A #15 blade carbon steel scalpel blade will be used on ½ of the incision; a cautery device with the above-mentioned settings will be used on the other ½ of the wound. The patient will be randomly assigned to receive the cautery incision on the left or right side. The same surgeon will make all of the skin incisions and perform the skin closures in order to provide as much standardization as possible.~The closure will be standardized.
Study NCT00305890 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Behavioral Weight Management Program
Description: The lifestyle behavioral weight management program will focus on lifestyle, exercise, attitudes, relationships, and nutrition. Participants will attend 12 weekly group sessions, followed by 6 every-other-week group sessions.
Study NCT02345369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Locked Set Screw
Description: Fixation of hip fracture with intramedullary hip screw with locking of the set screw
Study NCT02345369 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unlocked Set Screw
Description: Fixation of hip fracture with intramedullary hip screw without locking of the set screw
Study NCT02292381 — intervention group
Intervention type: OTHER
Intervention: Isometric exercise
Study NCT01632306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel administered IV
Study NCT02229084 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P10s-PADRE/ MONTANIDE™ ISA 51 VG
Description: Eligible subjects will be enrolled and immunized by SC administration of P10s-PADRE vaccine on each of 3 separate occasions concurrent with chemotherapy.
Study NCT02229084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) (AC) will be administered concurrently every three weeks for four cycles followed by docetaxel (75 mg/m2) every three weeks for four cycles.
Study NCT02229084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) (AC) will be administered concurrently every three weeks for four cycles followed by docetaxel (75 mg/m2) every three weeks for four cycles.
Study NCT02229084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) (AC) will be administered concurrently every three weeks for four cycles followed by docetaxel (75 mg/m2) every three weeks for four cycles.~If docetaxel is not tolerated, paclitaxel (175mg/m2) may be used in its place.
Study NCT00615667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus (FK506)
Description: Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
Study NCT00448825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate + Cognitive Behavioral Therapy
Description: Topiramate up to 300 mg per day
Study NCT00448825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Cognitive Behavioral Therapy
Description: Placebo twice a day
Study NCT03385863 — intervention group
Intervention type: DRUG
Intervention: Surfactant, Pulmonary，Curosurf
Description: All NRDS were given an early endotracheal infusion of Curosuf, with an initial dose of 200mg/kg, and if the condition needed to be repeated. Compare the therapeutic effect of pulmonary surfactant of infants at different gestational ages and to investigate whether exogenous surfactant replacement therapy is effective for all newborns with RDS.
Study NCT03385863 — intervention group
Intervention type: OTHER
Intervention: Perinatal risk factors of NRDS
Description: Compare the perinatal risk factors that were closely related to NRDS between early preterm infants with RDS and near term/term infants with RDS.
Study NCT04172480 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: Peripheral blood sampling on EDTA
Study NCT01198938 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin 5 mg sublingually given at 9 p.m. for 5 postoperative days or until discharge
Study NCT01687335 — intervention group
Intervention type: OTHER
Intervention: answering questionnare in differents time of the treatment
Study NCT00795158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desloratadine
Description: desloratadine 5 mg tablets; one tablet orally once a day for 28 days
Study NCT04377919 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry
Description: The patients will receive 2 capsules per day containing 500mg of cranberry extract for 8 weeks
Study NCT02051816 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apneic Oxygenation
Study NCT02051816 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscopy
Study NCT02051816 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Apneic Oxygenation
Study NCT01115803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2584702
Description: Supplied as 25 milligrams (mg) and 100 mg capsules, administered orally for two 28-day cycles.
Study NCT04377919 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patients will receive 2 capsules per day containing 500mg of maize starch for 8 weeks
Study NCT03796286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium-fiber bar
Description: Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
Study NCT01259297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150/300 mg once daily
Study NCT03796286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fiber bar
Description: Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
Study NCT03796286 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control bar (0 g fiber)
Description: Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
Study NCT01115803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Supplied as 25 mg, 100 mg, or 150 mg tablets, administered orally, daily for two 28-day cycles.~Starting dose is 150mg. Doses may be decreased in 50mg increments if necessary due to toxicity.
Study NCT01115803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Supplied as 5 mg or 10 mg tablets, administered orally, daily for two 28-day cycles.
Study NCT01407042 — intervention group
Intervention type: PROCEDURE
Intervention: mobile-bearing unicondylar knee arthroplasty
Description: mobile-bearing unicondylar knee arthroplasty
Study NCT00305890 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain-Coping Skills Training
Description: The pain-coping skills training will focus on minimizing maladaptive over-reactions and enhancing adaptive strategies to control and decrease pain. Participants will attend 12 weekly group sessions, followed by 6 every-other-week group sessions.
Study NCT01259297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine 5 mg
Study NCT01259297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Description: HCTZ 12.5/25 mg
Study NCT01259297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Aliskiren
Description: Placebo for Aliskiren 300 mg
Study NCT01259297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Aliskiren
Description: Placebo for Aliskiren 300 mg
Study NCT01259297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Amlodipine
Description: Placebo for Amlodipine
Study NCT01259297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Amlodipine
Description: Placebo for Amlodipine
Study NCT01259297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Hydrochlorothiazide (HCTZ)
Description: Placebo for HCTZ 12.5/25 mg
Study NCT01259297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Hydrochlorothiazide (HCTZ)
Description: Placebo for HCTZ 12.5/25 mg
Study NCT02771808 — intervention group
Intervention type: OTHER
Intervention: biomarker samples
Description: biomarker samples for haptoglobin genotype (RT-PCR) and phenotype (hemoglobin electrophoresis) general markers for oxidative stress (isoprostane f2 alpha, malondialdehyde) markers of inflammation (CRP, IL-1, 2, 6, 10 and TNF) markers of cardiac injury (CPK, troponins and BNP) markers of kidney injury (cystatin C, creatinine, GFR)
Study NCT03805295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BOKS Program
Description: 12-week physical activity program, occurring 3x/week, lasting 30-60 minutes per session.
Study NCT01084499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femara (Sequence 1)
Description: Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.
Study NCT01084499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peratra (Sequence 1)
Description: Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.
Study NCT01084499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femara (Sequence 2)
Description: Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.
Study NCT01084499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peratra (Sequence 2)
Description: Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.
Study NCT00638066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin
Description: 500 units of botulinum toxin for the second arm
Study NCT00638066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin A
Description: 250 units of botulinum toxin A once
Study NCT03814317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Treprostinil
Description: Inhaled treprostinil causes dilatation of the pulmonary arteries and may help reduce the pulmonary pressures in this studied population.~All subjects will initiate inhaled treprostinil at a dose of 3 breaths (18 mcg) four times daily. Study drug doses escalations (additional one breath four times daily) can occur every three days with a maximum dosing regimen of up to 12 breaths (72 mcg) four times daily, as clinically tolerated.
Study NCT03177876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sinus lift implant placement Hydroxyapatite Nano particles
Description: shneiderian membrane elevation and augmentation with Hydroxyapatite Nano particles with simultaneous implant placement
Study NCT03177876 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sinus lift implant placement tenting
Description: shneiderian membrane elevation and augmentation with graft less tenting technique with simultaneous implant placement
Study NCT00418262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Titrating with oral administration of 0.25 mg/kg, 0.50 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with food.
Study NCT01789073 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Impact, Nestlé Health Science
Description: Oral Impact from Nestlé Health Science. An enteral nutritional supplement high in protein and with added immune-enhancing nutrients: arginine, fish oil and nucleotides. The intervention arm receives Oral Impact in an individually estimated dosage according to a protein requirement of 1.5 g/kg bodyweight/day (subtracted their habitual protein intake). Each patient receives this dosage orally the last 7 days prior to surgery.
Study NCT03132246 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draws
Description: The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.
Study NCT03245632 — intervention group
Intervention type: OTHER
Intervention: Carbapenem-Resistant Klebsiella pneumoniae
Description: no intervention, this is an obervational study.
Study NCT05104151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional bar
Description: Protein-based nutritional bar, providing 155 calories per bar
Study NCT05104151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Habits Intervention
Description: The participants included, will receive a nutritional intervention providing a caloric deficit of 500 calories, depending on their daily requirements, these daily requirements calculated according to the formula BMR (Basic Metabolic Rate). Also prescription of moderate physical activity from 60 to 90 minutes daily will be made.
Study NCT05104151 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Habits Intervention
Description: The participants included, will receive a nutritional intervention providing a caloric deficit of 500 calories, depending on their daily requirements, these daily requirements calculated according to the formula BMR (Basic Metabolic Rate). Also prescription of moderate physical activity from 60 to 90 minutes daily will be made.
Study NCT03196050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Handheld Device (Smart Phone)
Description: Handheld device will be used for 3 tasks:~1x per day: status update (how are you today?)~1x per week: 10 questions on general health status~1x per month: EORTC QLQ-C30 questionnaire
Study NCT03100331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing
Description: Comprehensive neuropsychological assessment and implementation of appropriate support and resources.